# To Access the Safety and Effects of Intravenous Administration of VIR-5818 Alone and in Combination With Pembrolizumab in Adult Participants With Locally Advanced or Metastatic HER2-Expressing Cancers

Source: https://onco.cc/trials/nct05356741/  
OnCo record `nct05356741` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of VIR-5818 run by Vir Biotechnology, Inc., now recruiting.

## Summary

To Access the Safety and Effects of Intravenous Administration of VIR-5818 Alone and in Combination With Pembrolizumab in Adult Participants With Locally Advanced or Metastatic HER2-Expressing Cancers is a phase 1/2 interventional study registered as NCT05356741 by Vir Biotechnology, Inc., with 645 participants planned, started 2022-04-13. Conditions recorded: Locally Advanced or Metastatic HER2-Expressing Cancers. Interventions recorded: VIR-5818 and pembrolizumab.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-11-03
- Tags: pipeline; ctgov-ingest
- Registry id: NCT05356741
- Phase: 1/2
- Setting: A Phase 1, Multicenter, Open-Label, First-in-Human Study of the Safety and Pharmacokinetics of VIR-5818 Alone and in Combination With Pembrolizumab in Participants With Locally Advanced or Metastatic HER2-Expressing Cancers
- Sponsor: Vir Biotechnology, Inc.
- Enrolled: 645

## Sources

- ClinicalTrials.gov NCT05356741: https://clinicaltrials.gov/study/NCT05356741

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- drugs: [VIR-5818](https://onco.cc/drugs/amx-818/)
- companies: [Amunix Pharmaceuticals](https://onco.cc/companies/amunix-pharmaceuticals/), [Merck KGaA (EMD Serono)](https://onco.cc/companies/merck-kgaa/), [Sanofi](https://onco.cc/companies/sanofi/)

---
JSON: https://onco.cc/api/v1/entities/nct05356741.json